$1.46
+2.10%Sep 23, 2026, 11:42 UTC
Engitix appointed Sonia Quaratino as Executive Vice President and Chief Medical Officer, a newly created role, effective from her board tenure since 2023.
Source:Sep 16, 2026, 20:00 UTC
Innate Pharma's strategic partnership with Sobi to license lacutamab in T-cell lymphoma became effective after antitrust waiting periods expired and closing conditions were met, triggering a USD 75 million payment.
Source:Aug 14, 2026, 16:17 UTC
Innate Pharma S.A. announced an equity raise of EUR 30 million.
Aug 14, 2026, 16:17 UTC
Innate Pharma S.A. announced a strategic partnership.
Source:Aug 10, 2026, 06:00 UTC
Innate Pharma and Sobi announced a strategic partnership to license lacutamab for T-cell lymphoma, with Sobi receiving exclusive global commercialization rights and potential full development rights.
Jul 21, 2026, 06:00 UTC
Innate Pharma announced the completion of enrollment in the Phase 1 dose escalation study of IPH4502, a novel Nectin-4 exatecan antibody-drug conjugate.
Source: